Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer

References

• Schwartz P E, Smith J P. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124–30
   PubMed Web of Science ®Google Scholar
• Berek J S, Hacker F H, Lagasse L D, Poth T, Resnick B, Nieberg R K. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables with disease status. Obstet Gynecol 1984; 64: 207–19
   PubMed Web of Science ®Google Scholar
• Vogl S E, Seltzer V, Calanog A. 'Second-effort' surgical resection for bulky ovarian cancer. Cancer 1984; 54: 2220–5
   PubMed Web of Science ®Google Scholar
• Janisch H, Schieder K, Koelbl H. Diagnostic versus therapeutic second-look surgery in patients with ovarian cancer. Baillieres Clin Obstet Gynecol 1989; 3: 191–200
   PubMedGoogle Scholar
• Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt Rasmussen K. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990; 37: 279–83
   PubMed Web of Science ®Google Scholar
• Clarke Pearson D L, Bancy L C, Dudzinski M, Heaston D, Creasman W T. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. JAMA 1986; 255: 627–70
   PubMed Web of Science ®Google Scholar
• Vardi J R, Tadros G H, Foemmel R, Shebes M. Plasma lipid-as-sociated sialic acid and serum CA-125 as indicators of disease status with advanced ovarian cancer. Obstet Gynecol 1989; 74: 379–83
   PubMed Web of Science ®Google Scholar
• Mogensen O, Mogensen B, Jakobsen A, Sell A. Measurement of the ovarian cancer-associated antigen CA-125 prior to second look operation. Eur J Cancer Clin Oncol 1988; 24: 1835–7
   PubMedGoogle Scholar
• McGuckin M A, Layton G T, Bailey M J, Hurst T, Khoo S K, Ward B G. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma—comparison with CA-125. Gynecol Oncol 1990; 37: 165–71
   PubMed Web of Science ®Google Scholar
• Høgdall C K, Høgdall E VS, Hørding U, et al. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol 1991; 43: 103–7
   PubMed Web of Science ®Google Scholar
• Ward B G. Serum assays in the management of ovarian carcinoma. Int J Gynecol Cancer 1992, Suppl 1: 10–8
   Google Scholar
• Høgdall C K, Høgdall E VS, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Preoperative plasma tetranectin as a prognostic maker in ovarian cancer patients. Scand J Clin Lab Invest 1993; 53: 741–6
   PubMed Web of Science ®Google Scholar
• Høgdall C K, Hørding U, Nørgaard-Pedersen B, Toftager-Larsen K, Clemmensen I. Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol 1994; 57: 175–8
   PubMed Web of Science ®Google Scholar
• Fuhlendorff J, Clemmensen I, Magnusson S. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialogylcoprotein receptors and cartilage proteoglycan core protein. Biochemistry 1987; 26: 6757–64
   PubMed Web of Science ®Google Scholar
• Nielsen H, Clemmensen I, Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 1993; 37: 39–42
   PubMed Web of Science ®Google Scholar
• Clemmensen I. Interaction of tetranectin with suphated polysaccharides and trypan blue. Scand J Clin Lab Invest 1989; 49: 719–25
   PubMed Web of Science ®Google Scholar
• Borregarrd N, Christensen L, Bjerrum O W, Birgens H S, Clemmensen I. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphates. J Clin Invest 1990; 85: 408–16
   PubMed Web of Science ®Google Scholar
• Høgdall C K, Høgdall E V, Jørgensen L N, Clemmensen I. Changes in plasma tetranectin following hip surgery with or without thrombotic complicatons. Thromb Res 1992; 67: 399–405
   PubMed Web of Science ®Google Scholar
• Danø K, Andreasen P A, Grøndhl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–226
   PubMed Web of Science ®Google Scholar
• Christensen L, Clemmensen I. Differences in tetranectin im-munoreactivity between benign and malignant breast tissue. Histochemistry 1991; 95: 427–33
   PubMedGoogle Scholar
• Christensen L, Johansen N, Jensen B A, Clemmensen I. Im-munohistochemical localization of a novel, human plasma protein, tetranctin, in human endoocrine tissues. Histochemistry 1987; 87: 195–9
   PubMedGoogle Scholar
• Høgdall C K, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 1993; 72: 2415–22
   PubMed Web of Science ®Google Scholar
• Jensen B A, McNair P, Hyldstrup L, Clemmensen I. Plasma tetranectin in healthy male and female individuals, measured by enzyme-linked immunosorbent assay. J Lab Clin Med 1987; 110: 612–7
   PubMed Web of Science ®Google Scholar
• Makar A P, Kristensen G B, Børmer O P, Tropé C G. CA-125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992; 45: 323–8
   PubMed Web of Science ®Google Scholar
• Ward B G, McGuckin M A, Ramm L E, et al. The management of ovarian cariconoma is improved by the use of cancer-associated serum antigen CA-125 assays. Cancer 1993; 71: 430–8
   PubMed Web of Science ®Google Scholar
• Clemmensen I, Petersen L C, Kluft C. Purification and characterization of a novel, oligomeric. plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156: 327–33
   PubMedGoogle Scholar
• Bast R C, Feeney M, Lazarus H, Nadler L M. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
   PubMed Web of Science ®Google Scholar
• Miller D S, Spirtos N M, Ballon S C, Cox R S, Soriero O M, Teng N N. Critical reassement of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic vallues in patinets with persistent cancer. Cancer 1992; 69: 502–10
   PubMed Web of Science ®Google Scholar
• Friedman J B, Weiss N S. Second thoughts about second-look laparatomy in advanced ovarian cancer. N Engl J Med 1990; 322: 1079–82
   PubMed Web of Science ®Google Scholar
• Høgdall C K, Sölétormos G, Nielsen D, Nørgaard-Pedersen B, Bombernowsky P, Clemmensen I. Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Onocologica 1993; 32: 631–6
   PubMed Web of Science ®Google Scholar